Antihistamines do not inhibit the flare induced by the intradermal injection of autologous plasma in chronic urticaria patients

European Annals of Allergy and Clinical Immunology

Volumn 41, Issue 6, 2009, Pages 181-186

  Asero, R ^a   Tedeschi, A ^b   Lorini, M ^b,c   Cugno, M ^b,c  

^a CLINICA SAN CARLO   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoreactivity; Chronic urticaria; Histamine; Skin testing

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; D DIMER; DESLORATADINE; PROTHROMBIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS PLASMA SKIN TEST; BLOOD LEVEL; CHRONIC URTICARIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; MALE; PROTEIN DETERMINATION; SKIN MANIFESTATION; SKIN TEST; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PLASMA; SKIN; SKIN TESTS; URTICARIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76049101327     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Grattan CE, WalUngton TB, Warin RP, Kennedy CT, Bradfield JW. A serological mediator in chronic idiopathic urticaria - a clinical immunological and histological evaluation. Br J Dermatol 1986; 114: 583-90.
2. Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine-releasing autoantibodies with functional properties of anti IgE in chronic urticaria. Clin Exp Allergy 1991; 21: 695-704.
3. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599-604.
4. Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of FcεRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96: 2606-12.
5. Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FcεRIα (α-subunit). J Allergy Clin Immunol 1998; 101: 672-6.
6. Greaves MW. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664-72.
7. Fagiolo U, Kricek F, Ruf C, Peserico A, Amadori A, Cancian M. Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 2000; 106: 567-72.
8. Greaves MW, O'Donnell BF. Not all chronic urticaria is "idiopathic". Exp Dermatol 1998; 7: 11-3.
9. Greaves MW. Chronic urticaria. N Engl J Med 1995; 332: 1767-72.
10. Grattan CE. Autoimmune urticaria. Immunol Allergy Clin North Am 2004; 24: 163-81.
11. Fagiolo U, Cancian M, Bertollo L, Peserico A, Amadori A. Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 103: 1143-7.
12. Asero R, Tedeschi A, Lorini M, Salimbeni R, Zanoletti T, Miadonna A. Chronic urticaria: novel clinical and serological aspects. Clin Exp Allergy 2001; 31: 1105-10.
13. Greaves MW. Pathophysiology of chronic urticaria. Int Arch Allergy Immunol. 2002; 127: 3-9.
14. Stadler BM, Miescher S, Horn M, et al. Allergic manifestations as the results of a conditional autoimmune response. Int Arch Allergy Immunol 2001; 124(1-3): 411-3.
15. Horn MP, Pachlopnik JM, Vogel M, et al. Conditional autoimmunity mediated by human natural anti-Fc(epsilon)RIalpha autoantibodies? FASEB J 2001; 15: 2268-74.
16. Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117: 1113-7.
17. Asero R, Tedeschi A, Coppola R, et al. Activation of the tissue pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007; 119: 705-10.
18. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008; 63: 176-80.
19. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 2009; 148: 170-4.
20. Sabroe RA, Fiebiger E, Francis DM, et al. Classification of anti-FcεRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002; 110: 492-9.
21. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CEH. EAACI/GALEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009; 64: 1256-68.
22. Asero R, Lorini M, Suli C, Tedeschi A. NSAID intolerance in chronic idiopathic urticaria : a study of its relationship with histamine releasing activity of patients' sera. Allergol Immunopathol (Madr) 2001; 29: 119-22.
23. Sabroe RA, Grattan CE, Francis DM, Barr RM, Kobza Black A, Greaves MW. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 446-52.
24. Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, Cugno M. Plasma levels and skin-eosinophil-expression of vascular endothelial growth factor (VEGF) in patients with chronic urticaria. Allergy 2009; 64(11): 1616-22.
25. Tedeschi A, Lorini M, Asero R. No evidence of increased serum substance P levels in chronic urticaria patients with and without demonstrable circulating vasoactive factors. Clin Exp Dermatol 2005; 30: 171-5.
26. Borici-Mazi R, Kouridakis S, Kontou-Fili K. Cutaneous responses to substance P and calcitonine gene-related peptide in chronic urticaria: the effect of cetirizine and dimethindene. AUergy 1999; 54: 46-56.
27. Cappugi P, Tsampau D, Lotti T. Substance P provokes cutaneous erythema and edema through a histamine-independent pathway. Int J Dermatol 1992; 31: 206-9.
28. Wedi B, Novacovic V, Koerner M, Kapp A. Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression - inhibitory effects of anti-inflammatory drugs. J Allergy Clin Immunol 2000; 105: 552-60.
29. Schaeffer RC, Gong F, Bitrick MS, Smith TL. Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am J Physiol 1993; 264: 1798-809.
30. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maranganore JM, Stone SR. Thrombin functions as an inflammatory mediator through activation of its receptors. J Exp Med 1996; 183: 821-7.
31. Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984; 133: 3282-5.
32. Vliagoftis H. Thrombin induces mast cell adhesion to fibronectin: evidence for the involvement of protease-activated Receptor-1. J Immunol 2002; 169: 4551-8.
33. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nature Medicine 2006; 12: 682-7.